BioCryst Pharmaceuticals, Inc. - Laporan Laba Rugi (TTM)

BioCryst Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US09058V1035

Laporan Laba Rugi (TTM)

Laporan Laba Rugi BioCryst Pharmaceuticals, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 54 18 32 79 114 157 188 204 238 271 290 307 318 331 355 382 413 451 503 558
Change (%) -66.72 79.92 146.93 44.09 37.83 19.64 8.28 17.11 13.58 6.96 5.85 3.56 4.36 7.24 7.55 7.94 9.24 11.71 10.73
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 119 125 143 169 188 216 233 242 248 260 244 234 225 217 215 202 199 186 180 187
Change (%) 5.14 14.75 17.98 11.15 15.20 8.00 3.87 2.38 4.74 -6.26 -4.12 -3.57 -3.81 -0.72 -5.99 -1.83 -6.34 -3.18 3.81
% of Revenue 221.50 699.75 446.29 213.23 164.49 137.48 124.10 119.04 104.07 95.96 84.10 76.17 70.93 65.37 60.52 52.90 48.11 41.25 35.75 33.52
Gross Operating Profit -65 -107 -111 -90 -74 -59 -45 -39 -10 11 46 73 92 115 140 180 214 265 323 371
Change (%) 64.28 3.88 -19.26 -17.94 -19.90 -23.07 -14.46 -74.99 -212.79 321.21 58.61 26.35 24.31 22.26 28.31 18.91 23.69 22.17 14.58
% of Revenue -121.50 -599.75 -346.29 -113.23 -64.49 -37.48 -24.10 -19.04 -4.07 4.04 15.90 23.83 29.07 34.63 39.48 47.10 51.89 58.75 64.25 66.48
SG&A 52 63 74 87 97 119 131 143 152 159 173 186 200 214 225 235 250 266 289 315
Change (%) 20.03 17.36 17.34 12.46 21.97 10.24 8.93 6.26 5.12 8.52 7.50 7.38 6.95 5.44 4.55 6.13 6.49 8.64 9.04
% of Revenue 97.92 353.15 230.34 109.46 85.43 75.60 69.66 70.08 63.58 58.85 59.71 60.64 62.88 64.43 63.36 61.59 60.56 59.03 57.41 56.53
R&D
Change (%)
% of Revenue
OpEx 171 188 217 255 285 335 364 385 400 419 417 420 425 430 440 438 448 452 469 502
Change (%) 9.70 15.62 17.76 11.60 17.52 8.79 5.69 3.82 4.88 -0.64 0.71 1.29 1.24 2.34 -0.60 2.45 0.81 3.77 7.03
% of Revenue 319.42 1,052.90 676.63 322.69 249.92 213.08 193.76 189.11 167.65 154.81 143.80 136.81 133.81 129.81 123.88 114.49 108.67 100.28 93.16 90.05
Operating Income -117 -170 -185 -176 -171 -178 -176 -181 -161 -148 -127 -113 -107 -99 -85 -55 -36 -1 34 55
Change (%) 44.53 8.88 -4.64 -3.00 3.96 -0.80 2.92 -11.10 -7.98 -14.51 -11.05 -4.89 -7.98 -14.10 -34.72 -35.41 -96.43 -2,792.42 61.06
% of Revenue -219.42 -952.90 -576.63 -222.69 -149.92 -113.08 -93.76 -89.11 -67.65 -54.81 -43.80 -36.81 -33.81 -29.81 -23.88 -14.49 -8.67 -0.28 6.84 9.95
Interest Expense -12 -15 -24 -35 -46 -59 -70 -81 -91 -99 -103 -108 -110 -108 -105 -101 -99 -99 -98 -94
Change (%) 21.05 67.97 43.42 32.03 28.56 18.44 14.99 13.20 8.40 3.59 4.77 2.39 -1.70 -2.67 -3.97 -2.49 -0.14 -1.03 -3.23
% of Revenue -22.38 -81.41 -76.00 -44.15 -40.45 -37.73 -37.35 -39.66 -38.34 -36.59 -35.44 -35.07 -34.68 -32.66 -29.64 -26.47 -23.91 -21.86 -19.37 -16.92
Net Income -125 -183 -209 -214 -227 -184 -194 -210 -193 -247 -226 -243 -236 -227 -209 -146 -124 -89 -53 -36
Change (%) 46.32 14.60 2.19 5.93 -18.84 5.39 8.07 -7.77 27.80 -8.44 7.28 -2.62 -4.15 -7.93 -30.04 -15.15 -28.22 -39.84 -33.21
% of Revenue -233.45 -1,026.35 -653.70 -270.53 -198.88 -117.11 -103.16 -102.96 -81.09 -91.24 -78.10 -79.15 -74.43 -68.36 -58.69 -38.18 -30.01 -19.72 -10.62 -6.41

Source: Capital IQ

Other Listings
MX:BCRX
DE:BO1 € 7.00
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista